Guidance
← 실적 발표
01
02
03
04 05 06
톤
AI
TMO
FY2026 Q1
상향
Thermo Fisher Scientific Inc 실적 발표
Buzzberg 분석
Company raises full-year revenue and EPS guidance.
Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%).
Buzzberg 분석 Company raises full-year revenue and EPS guidance. Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%). 전체 분석 보기분석 접기
Thermo Fisher reported a strong Q1 with 6% revenue growth and raised full-year guidance, driven by bioproduction and clinical research strength. Management highlighted AI collaborations with NVIDIA and OpenAI but gave no specific cross-company signals beyond partnership status. The call focused on internal execution, margin expansion, and macro hedging for inflation. Q1 revenue $11.01B (+6% reported, +1% organic); adjusted EPS $5.44 (+6%).
- Full-year revenue guidance raised to $47.3-$48.1B, EPS to $24.64-$25.12.
- Biopharma end market led growth; academic/government and diagnostics were soft.
- Completed Clario acquisition ($9B) and highlighted NVIDIA and OpenAI collaborations.
매출$11.005B-10% 전분기 대비
주당순이익(EPS)$5.44-17% 전분기 대비
매출총이익률40.67%보고값
영업이익률16.93%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
M&A
Clario acquisition completed, contributing to guidance.
Demand
Clinical research business delivering strong growth and share gains.
핵심 내용 3개 더 보기
AI
AI collaboration with NVIDIA progressing toward commercialization.
Margins
Tariffs and related FX impact Q1 margins by 80 bps.
Macro
Higher inflation placeholder in guidance for future quarters.
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $11.005B | -10% 전분기 대비 |
| 주당순이익(EPS) | $5.44 | -17% 전분기 대비 |
| 매출총이익률 | 40.67% | 보고값 |
| 영업이익률 | 16.93% | 보고값 |
| 잉여현금흐름 | $0.816B | 보고값 |
| 자본지출 | $0.376B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 자본지출 | FY2026 | $1.9B–$2.1B | $2B | 제시 |
| 주당순이익(EPS) | FY2026 | $24.64–$25.12 | $24.88 | 상향 |
| 주당순이익(EPS) | FY2026 Q2 | $5.69–$5.74 | $5.71 | 제시 |
| 잉여현금흐름 | FY2026 | $6.9B–$7.4B | $7.15B | 제시 |
| 매출 | FY2026 | $47.3B–$48.1B | $47.7B | 상향 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management expressed confidence in meeting guidance and highlighted strong execution, innovation, and strategic acquisitions as drivers of future growth.
경영진의 AI 분석
Management discussed AI adoption as a positive tailwind, citing collaborations with NVIDIA and OpenAI, and believes AI will accelerate scientific discovery and enhance their competitive advantage. They are embedding AI across instruments and clinical research to improve customer outcomes.
아래에 언급된 기업 2개 모두 표시
기업발표 이후 수익률
파트너
파트너
Mark Casper
Thermo Fisher is integrating NVIDIA's AI into lab instruments to create commercial workflow solutions, potentially boosting NVIDIA's presence in life sciences.
근거
“We announced a strategic collaboration with NVIDIA, combining our leadership and laboratory technologies with Navidius advanced AI capabilities.”
OPENAI
파트너
Mark Casper
Thermo Fisher's earlier collaboration with OpenAI is supporting clinical research AI tools, though no new specifics were provided.
근거
“we had announced some time ago with open Ai and you know customers value that and that position is very well”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 2개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.